CTIS2022-501243-33-00招募中1 期
A Phase 2 Open-label Clinical Study to Evaluate the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma(waveLINE-004) - MK2140-004
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 129
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Has relapsed or refractory (rr) diffuse large B-cell lymphoma diffused large B-cell lymphoma (DLBCL); has progressed after at least 2 lines of prior therapy; and has progressed after auto- stem cell transplant (SCT) or are auto-SCT ineligible. Must have received prior multiagent regimen that includes an alkylating agent. anthracycline, and anti-CD20 (cluster of differentiation 20) monoclonal antibody., Has histologically confirmed diagnosis of DLBCL., Has radiographically measurable DLBCL per the Lugano Response Criteria, Should either be post- chimeric antigen receptor T cell therapy (CAR-T) failure or ineligible for CAR-T (for any reason), Life expectancy of at least 3 months, Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 assessed within 7 days before time of enrollment, Has adequate organ function
排除标准
- •Has received a diagnosis of primary mediastinal B-cell lymphoma (PMBCL), Has received prior systemic anticancer therapy, including investigational agents within 4 weeks prior to the first dose of study intervention, Has received prior radiotherapy within 28 days of start of study intervention. Participants must have recovered from all radiation-related toxicities, Has ongoing corticosteroid therapy (exceeding 30 mg daily of prednisone equivalent), Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention, Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks before the first dose of study intervention, Has known active central nervous system (CNS) lymphoma involvement or active CNS involvement by lymphoma, Has an active infection requiring systemic therapy, Has a known history of human immunodeficiency virus (HIV) infection, Has a known history of hepatitis B or known active hepatitis C virus (HCV), Has undergone solid organ transplant at any time, Has a history of any clinically significant cardiovascular conditions within 6 months of screening or serious cardiac arrhythmia requiring medication, Has known history of liver cirrhosis, Has pericardial effusion or clinically significant pleural effusion, Has ongoing Grade >1 peripheral neuropathy, Has a history of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years, Transformed DLBCL from indolent lymphoma, In participants with prior allo-SCT, acute graft versus host disease (GVHD) or ongoing evidence of chronic GVHD
研究者
相似试验
进行中（未招募）
1 期
A Research Study, where the participant and healthcare providers are aware of the treatment being given, to evaluate safety and effectiveness of medication MK-2140 in patients with Diffuse Large B Cell Lymphoma who failed prior therapies.EUCTR2021-003397-32-GRMerck Sharp & Dohme LLC., a subsidiary of Merck & Co.,Inc.100
进行中（未招募）
1 期
A Research Study, where the participant and healthcare providers are aware of the treatment being given, to evaluate safety and effectiveness of medication MK-2140 in patients with Diffuse Large B Cell Lymphoma who failed prior therapies.Treatment of participants with Relapsed or Refractory Diffuse Large B-Cell LymphomaMedDRA version: 21.0Level: PTClassification code 10012818Term: Diffuse large B-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-003397-32-ESMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.100
进行中（未招募）
1 期
A Research Study, where the participant and healthcare providers are aware of the treatment being given, to evaluate safety and effectiveness of medication MK-2140 in patients with Diffuse Large B Cell Lymphoma who failed prior therapies.Treatment of participants with Relapsed or Refractory Diffuse Large BCell LymphomaMedDRA version: 21.0Level: PTClassification code 10012818Term: Diffuse large B-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-003397-32-ITMERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.100
进行中（未招募）
1 期
A Research Study, where the participant and healthcare providers are aware of the treatment being given, to evaluate safety and effectiveness of medication MK-2140 in patients with Diffuse Large B Cell Lymphoma who failed prior therapies.Treatment of participants with Relapsed or Refractory Diffuse Large B-Cell LymphomaMedDRA version: 21.0Level: PTClassification code 10012818Term: Diffuse large B-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-003397-32-PLMerck Sharp & Dohme LLC100
进行中（未招募）
1 期
A Research Study, where the participant and healthcare providers are aware of the treatment being given, to evaluate safety and effectiveness of medication MK-2140 in patients with Diffuse Large B Cell Lymphoma who failed prior therapies.Treatment of participants with Relapsed or Refractory Diffuse Large B-Cell LymphomaMedDRA version: 21.0Level: PTClassification code 10012818Term: Diffuse large B-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-003397-32-NOMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.100